These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

744 related articles for article (PubMed ID: 27993859)

  • 1. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
    Zavascki AP; Nation RL
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
    Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin- and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury.
    Pike M; Saltiel E
    J Pharm Pract; 2014 Dec; 27(6):554-61. PubMed ID: 25237156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
    Phe K; Lee Y; McDaneld PM; Prasad N; Yin T; Figueroa DA; Musick WL; Cottreau JM; Hu M; Tam VH
    Antimicrob Agents Chemother; 2014 May; 58(5):2740-6. PubMed ID: 24566187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymyxin B vs. colistin: the comparison of neurotoxic and nephrotoxic effects of the two polymyxins.
    Aysert-Yildiz P; Özgen-Top Ö; Şentürk AF; Kanik S; Özger HS; Dizbay M
    BMC Infect Dis; 2024 Aug; 24(1):862. PubMed ID: 39187812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
    Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
    Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methionine Ameliorates Polymyxin-Induced Nephrotoxicity by Attenuating Cellular Oxidative Stress.
    Azad MAK; Sivanesan S; Wang J; Chen K; Nation RL; Thompson PE; Roberts KD; Velkov T; Li J
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
    Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Polymyxins: Implications for Therapeutic Use.
    Nation RL; Forrest A
    Adv Exp Med Biol; 2019; 1145():219-249. PubMed ID: 31364081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity.
    Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):431-4. PubMed ID: 19733029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colistin and polymyxin B: peas in a pod, or chalk and cheese?
    Nation RL; Velkov T; Li J
    Clin Infect Dis; 2014 Jul; 59(1):88-94. PubMed ID: 24700659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies.
    Oliota AF; Penteado ST; Tonin FS; Fernandez-Llimos F; Sanches AC
    Diagn Microbiol Infect Dis; 2019 May; 94(1):41-49. PubMed ID: 30635223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymyxin B versus colistin: an update.
    Cai Y; Lee W; Kwa AL
    Expert Rev Anti Infect Ther; 2015; 13(12):1481-97. PubMed ID: 26488563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study.
    Yang QJ; Xiang BX; Song MH; Yang CY; Liang JH; Xie YL; Zuo XC
    Pharmacotherapy; 2024 Aug; 44(8):631-641. PubMed ID: 39046197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymyxin B, colistin, and sodium colistimethate.
    Horton J; Pankey GA
    Med Clin North Am; 1982 Jan; 66(1):135-42. PubMed ID: 6278236
    [No Abstract]   [Full Text] [Related]  

  • 18. Polymyxin B and colistin-the economic burden of nephrotoxicity against multidrug resistant bacteria.
    Tuon FF; Rocha JL; Gasparetto J
    J Med Econ; 2019 Feb; 22(2):158-162. PubMed ID: 30466325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity.
    Manchandani P; Zhou J; Babic JT; Ledesma KR; Truong LD; Tam VH
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
    Kassamali Z; Danziger L
    Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.